S-309309 Explained

Legal Status:	Investigational
Cas Number:	2267352-04-3
Pubchem:	153266620
Iupac Name:	N-[(4''R'')-5,7-difluoro-2'-(5-methylpyridin-2-yl)-4'-oxospiro[2,3-dihydrochromene-4,6'-5,7-dihydropyrazolo[4,3-c]pyridine]-3'-yl]-2-methylsulfonylacetamide
C:	23
H:	21
F:	2
N:	5
O:	5
S:	1
Smiles:	FC1=C2[C@@]3(CC=4C(C(=O)N3)=C(NC(CS(C)(=O)=O)=O)N(N4)C5=CC=C(C)C=N5)CCOC2=CC(F)=C1
Stdinchi:	1S/C23H21F2N5O5S/c1-12-3-4-17(26-10-12)30-21(27-18(31)11-36(2,33)34)19-15(29-30)9-23(28-22(19)32)5-6-35-16-8-13(24)7-14(25)20(16)23/h3-4,7-8,10H,5-6,9,11H2,1-2H3,(H,27,31)(H,28,32)/t23-/m0/s1
Stdinchikey:	WWHHALBVCASKPG-QHCPKHFHSA-N

S-309309 is an experimental MGAT2 inhibitor developed as an anti-obesity drug by the Japanese company Shionogi.^[1] ^[2] Phase II trial results are expected in late 2023.^[3]

Notes and References

S-309309: A Novel Selective Inhibitor of MGAT2 That Exert Potent Anti-Obesity Effect in DIO MiceKato, Hideaki; Takemoto, Kosuke, MS; Higashino, Kenichi. Obesity; Silver Spring Vol. 30, (Nov 2022): 277-278.
MGAT2 Inhibition Activates NTS Neurons, Leading to Appetite Suppression and Beneficial EffectsTakemoto, Kosuke, MS; Kato, Hideaki; Higashino, Kenichi. Obesity; Silver Spring Vol. 30, (Nov 2022): 278-279.
News: Beaney . Abigail . Obesity: Six trials to watch over the next 12 months . 5 December 2023 . Clinical Trials Arena . 30 June 2023.